SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biocryst Pharmaceuticals Inc (BCRX) -- Ignore unavailable to you. Want to Upgrade?

To: keokalani'nui who wrote (111)3/27/2007 4:25:24 PM
From: tom pope  Read Replies (2) | Respond to of 269
 
E-mail is time stamped 15:51, but I'm not sure that means much.

He attributes the drop to instability of the IV formulation of Fodosine . Is that an odd way to characterize vial cap contamination, or is there more to the story than the vial caps?

EDIT - the reason I say that the e-mail time stamp may not mean much is that the e-mail is simply a link to his site. There's no indication there when he posted.



To: keokalani'nui who wrote (111)3/28/2007 11:53:28 AM
From: keokalani'nui  Respond to of 269
 
I shoulda listened to the CC as Tuck must have. t-cell-all cr's are lower than at interim. Maybe rethink the t-cell-all market after all.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News